{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:32:20Z","timestamp":1770755540389,"version":"3.50.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":1015,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["RRC-2022-23680775"],"award-info":[{"award-number":["RRC-2022-23680775"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["20\/1819"],"award-info":[{"award-number":["20\/1819"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RRC\u20102022\u201023680775"],"award-info":[{"award-number":["RRC\u20102022\u201023680775"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["20\/1819"],"award-info":[{"award-number":["20\/1819"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Iron deficiency is a common finding among patients with heart failure (HF) and is associated with adverse outcomes, including decreased quality of life, increased risk of hospitalization, and decreased survival. Intravenous ferric carboxymaltose (FCM) has been shown to improve outcomes among patients with HF and concomitant iron deficiency, but FCM is associated with an increased risk of hypophosphataemia. We aimed to better characterize this risk among HF populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This pooled analysis examined data from 41 studies of adults with iron deficiency across disease states and therapeutic areas. Among the 7931 patients treated with FCM available for analysis, 14% made up the HF subgroup. Additional subgroups included women's health (36%), non\u2013dialysis-dependent chronic kidney disease (NDD-CKD; 27%), haemodialysis-dependent chronic kidney disease (HD-CKD; 1%), gastrointestinal (10%), neurology (3%), and other (10%). The incidence of post-baseline moderate or severe hypophosphataemia (i.e. serum phosphate [PO43\u2212] level &amp;lt;2.0 mg\/dL) varied across the therapeutic areas, with the lowest incidences observed in the HD-CKD (0%), HF (8.1%), and NDD-CKD (12.8%) subgroups. The prevalence of moderate or severe hypophosphataemia among the women's health, other, gastrointestinal, and neurology subgroups was 30.1%, 40.6%, 51.0%, and 55.6%, respectively. In the HF subgroup, one patient (&amp;lt;0.1%) had a serum PO43\u2212 of &amp;lt;1.0 mg\/dL recorded, compared with 4.8% and 4.0% of the subjects in the neurology and gastrointestinal groups, respectively. With the exception of the HD-CKD subgroup, mean serum PO43\u2212 levels decreased through weeks 2 to 4, and then returned toward baseline and plateaued by week 8. The strongest predictor of hypophosphataemia was preserved kidney function (estimated glomerular filtration rate: &amp;gt;60 mL\/min\/1.73 m2 vs. &amp;lt;30 mL\/min\/1.73 m2; odds ratio: 12.2). Among patients in the HF subgroup, the incidence of treatment-emergent adverse events potentially related to hypophosphataemia (e.g. cardiac failure, ventricular tachyarrhythmias, fatigue, muscle weakness, bone pain, neurological symptoms, and muscle pain) was lower among FCM-treated patients than among those receiving placebo, and lower among patients with a post-baseline PO43\u2212 &amp;lt;2 mg\/dL vs. those not meeting such criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The risk of laboratory-assessed hypophosphataemia in HF patients treated with FCM was lower than that seen in patients in other therapeutic areas treated with FCM, and clinical events associated with hypophosphataemia are uncommon with FCM therapy in this population. Appropriate monitoring, particularly soon after administration in the unlikely event of repeated dosing in HF patients, will allow for further refinement of management strategies. [Correction added on 24 February 2023, after first online publication: In the preceding sentence, \u201c\u2026administration, will allow\u2026\u201d has been corrected to \u201c\u2026administration in the unlikely event of repeated dosing in HF patients, will allow\u2026\u201d in this version.]<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14286","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T04:53:46Z","timestamp":1675227226000},"page":"1294-1304","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hypophosphataemia Risk Associated with Ferric Carboxymaltose in Heart Failure: A Pooled Analysis of Clinical Trials"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-2263","authenticated-orcid":false,"given":"Giuseppe MC","family":"Rosano","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, IRCCS San Raffaele Roma , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Kidney Transplantation, University of California , Irvine, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa A.","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroc\u0142aw Medical University , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"2026012114114723900_ehf214286-bib-0001","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3945\/ajcn.114.103366","article-title":"Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review","volume":"102","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"2026012114114723900_ehf214286-bib-0002","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ajh.24820","article-title":"Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management","volume":"92","author":"Cappellini","year":"2017","journal-title":"Am J Hematol"},{"key":"2026012114114723900_ehf214286-bib-0003","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1474-4422(18)30311-9","article-title":"Comorbidities, treatment, and pathophysiology in restless legs syndrome","volume":"17","author":"Trenkwalder","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012114114723900_ehf214286-bib-0004","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/metabo12020129","article-title":"Iron metabolism in normal and pathological pregnancies and fetal consequences","volume":"12","author":"M\u00e9gier","year":"2022","journal-title":"Metabolites"},{"key":"2026012114114723900_ehf214286-bib-0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijgo.2014.09.027","article-title":"Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey","volume":"128","author":"Fraser","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"key":"2026012114114723900_ehf214286-bib-0006","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"2026012114114723900_ehf214286-bib-0007","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jacc.2017.12.027","article-title":"The burden of iron deficiency in heart failure: therapeutic approach","volume":"71","author":"Rocha","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114114723900_ehf214286-bib-0008","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP registry","volume":"106","author":"von Haehling","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2026012114114723900_ehf214286-bib-0009","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2026012114114723900_ehf214286-bib-0010","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114114723900_ehf214286-bib-0011","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cardfail.2011.08.003","article-title":"Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure","volume":"17","author":"Jankowska","year":"2011","journal-title":"J Card Fail"},{"key":"2026012114114723900_ehf214286-bib-0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study","volume":"174","author":"Enjuanes","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026012114114723900_ehf214286-bib-0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens","year":"2018","journal-title":"Acta Cardiol"},{"key":"2026012114114723900_ehf214286-bib-0014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11739-020-02434-9","article-title":"Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting","volume":"16","author":"Marchi","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2026012114114723900_ehf214286-bib-0015","article-title":"Chronic heart failure: clinical implications of iron homeostasis disturbances revisited","volume":"14","author":"Suciadi","year":"2022","journal-title":"Cureus"},{"key":"2026012114114723900_ehf214286-bib-0016","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ejhf.2251","article-title":"Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure","volume":"24","author":"Graham","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114114723900_ehf214286-bib-0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol Aspects Med"},{"key":"2026012114114723900_ehf214286-bib-0018","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012114114723900_ehf214286-bib-0019","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114114723900_ehf214286-bib-0020","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"2026012114114723900_ehf214286-bib-0021","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026012114114723900_ehf214286-bib-0022","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2169\/naika.71.1566","article-title":"2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide","volume":"71","author":"Okada","year":"1982","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"2026012114114723900_ehf214286-bib-0023","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.3390\/jcm9113587","article-title":"A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose","volume":"9","author":"Rosano","year":"2020","journal-title":"J Clin Med"},{"key":"2026012114114723900_ehf214286-bib-0024","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tmrv.2020.07.002","article-title":"Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis","volume":"34","author":"Bellos","year":"2020","journal-title":"Transfus Med Rev"},{"key":"2026012114114723900_ehf214286-bib-0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"2026012114114723900_ehf214286-bib-0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"2026012114114723900_ehf214286-bib-0027","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects \u2013 hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"2026012114114723900_ehf214286-bib-0028","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fendo.2018.00267","article-title":"Physiological actions of fibroblast growth factor-23","volume":"9","author":"Erben","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026012114114723900_ehf214286-bib-0029","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.amjmed.2005.02.014","article-title":"Hypophosphatemia: an update on its etiology and treatment","volume":"118","author":"Gaasbeek","year":"2005","journal-title":"Am J Med"},{"key":"2026012114114723900_ehf214286-bib-0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5049\/EBP.2014.12.1.19","article-title":"Association between hypophosphatemia and cardiac arrhythmias in the early stage of sepsis: could phosphorus replacement treatment reduce the incidence of arrhythmias?","volume":"12","author":"Schwartz","year":"2014","journal-title":"Electrolyte Blood Press"},{"key":"2026012114114723900_ehf214286-bib-0031","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.amjms.2016.04.013","article-title":"Hypophosphatemia-induced cardiomyopathy","volume":"352","author":"Ariyoshi","year":"2016","journal-title":"Am J Med Sci"},{"key":"2026012114114723900_ehf214286-bib-0032","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00007611-199401000-00014","article-title":"Ventricular tachycardia in acute myocardial infarction: the role of hypophosphatemia","volume":"87","author":"Ognibene","year":"1994","journal-title":"South Med J"},{"key":"2026012114114723900_ehf214286-bib-0033","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jcph.1754","article-title":"Hypophosphatemia is common after intravenous ferric carboxymaltose infusion among patients with symptomatic heart failure with reduced ejection fraction","volume":"61","author":"Dashwood","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2026012114114723900_ehf214286-bib-0034","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.jacc.2018.03.448","article-title":"High-dose ferric carboxymaltose in patients with HFrEF induces significant hypophosphatemia","volume":"71","author":"St\u00f6hr","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114114723900_ehf214286-bib-0035","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"US Department of Health and Human Services","year":"2009"},{"key":"2026012114114723900_ehf214286-bib-0036","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"US Department of Health and Human Services","year":"2017"},{"key":"2026012114114723900_ehf214286-bib-0037","volume-title":"Injectafer [package insert]"},{"key":"2026012114114723900_ehf214286-bib-0038"},{"key":"2026012114114723900_ehf214286-bib-0039","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000324","article-title":"Prevalence and prognostic impact of kidney disease on heart failure patients","volume":"3","author":"L\u00f6fman","year":"2016","journal-title":"Open Heart"},{"key":"2026012114114723900_ehf214286-bib-0040","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehv010","article-title":"The kidney in heart failure: an update","volume":"36","author":"Damman","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114114723900_ehf214286-bib-0041","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.0000116764.53225.A9","article-title":"Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study","volume":"109","author":"McAlister","year":"2004","journal-title":"Circulation"},{"key":"2026012114114723900_ehf214286-bib-0042","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4103\/2230-8210.183457","article-title":"Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: a study from a tertiary care hospital in India","volume":"20","author":"Vikrant","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"2026012114114723900_ehf214286-bib-0043","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/970245","article-title":"Phosphate metabolism in CKD stages 3\u20135: dietary and pharmacological control","volume":"2011","author":"Ketteler","year":"2011","journal-title":"Int J Nephrol"},{"key":"2026012114114723900_ehf214286-bib-0044","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2369-14-14","article-title":"Mineral metabolism and outcomes in chronic kidney disease stage 2\u20134 patients","volume":"14","author":"Chartsrisak","year":"2013","journal-title":"BMC Nephrol"},{"key":"2026012114114723900_ehf214286-bib-0045","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008100","article-title":"Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design","volume":"14","author":"Mentz","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026012114114723900_ehf214286-bib-0046","author":"U.S. National Library of Medicine"},{"key":"2026012114114723900_ehf214286-bib-0047","first-page":"2083","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"S0140-6736","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2026012114114723900_ehf214286-bib-0048","doi-asserted-by":"crossref","first-page":"267","DOI":"10.12809\/hkmj219354","article-title":"Intravenous iron isomaltoside (Monofer)-induced hypophosphataemia: a case report","volume":"28","author":"Wong","year":"2022","journal-title":"Hong Kong Med J"},{"key":"2026012114114723900_ehf214286-bib-0049","first-page":"gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","author":"Zoller","year":"2022","journal-title":"Gut"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14286","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1294\/65051368\/eschf_10_2_1294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1294\/65051368\/eschf_10_2_1294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:13:07Z","timestamp":1769022787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/2\/1294\/8304910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14286","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"2022-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}